Article Figures & Data
Figures
- FIG 1
Summary of dalbavancin activity when tested against S. aureus isolates with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. medical centers. Abbreviations: VAN ≥2, isolates with vancomycin MICs of ≥2 mg/liter; DAPTO-NS, daptomycin nonsusceptible (MIC, ≥2 mg/liter); TLV ≥0.12 mg/liter, isolates with telavancin MICs of ≥0.12 mg/liter; TEICO ≥4, isolates with teicoplanin MICs of ≥4 mg/liter; LNZ-R, linezolid resistant.
Tables
- TABLE 1
Activity of dalbavancin and comparator antimicrobial agents tested against S. aureus isolates with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. medical centers
Organism subset and antimicrobial agent MIC50 (mg/liter) MIC90 (mg/liter) MIC range (mg/liter) CLSIa EUCASTa %S %R %S %R Vancomycin MIC ≥2 mg/liter (n = 1,141) Dalbavancin 0.06 0.12 ≤0.03 to 0.5 99.3b 95.5 4.5 Daptomycin 0.5 1 ≤0.12 to 4 96.8 96.8 3.2 Vancomycin 2 2 2 to 4 99.3 0.0 9.3 0.7 Teicoplanin ≤2 ≤2 ≤2 to 16 99.9 0.0 93.5 6.5 Linezolid 1 2 ≤0.12 to >8 99.6 0.4 99.6 0.4 Oxacillin >2 >2 ≤0.25 to >2 26.9 73.1 26.9 73.1 Daptomycin nonsusceptible (n = 48) Dalbavancin 0.06 0.12 ≤0.03 to 0.5 95.8b 91.7 8.3 Daptomycin 2 4 2 to 4 0.0 0.0 100.0 Vancomycin 2 2 1 to 4 95.8 0.0 95.8 4.2 Teicoplanin ≤2 4 ≤2 to 16 97.9 0.0 87.5 12.5 Linezolid 1 2 0.5 to 4 100.0 0.0 100.0 0.0 Oxacillin >2 >2 ≤0.25 to >2 12.5 87.5 12.5 87.5 Telavancin MIC ≥0.12 mg/liter (n = 52)c Dalbavancin 0.06 0.25 ≤0.03 to 0.5 90.4b 84.6 15.4 Daptomycin 0.5 1 0.25 to 2 96.2 96.2 3.8 Vancomycin 1 2 1 to 4 98.1 0.0 98.1 1.9 Telavancin 0.12 0.12 0.12 to 0.25 96.2 96.2 3.8 Teicoplanin ≤2 4 ≤2 to 16 98.1 0.0 76.9 23.1 Linezolid 1 1 0.25 to 2 100.0 0.0 100.0 0.0 Oxacillin >2 >2 ≤0.25 to >2 34.6 65.4 34.6 65.4 Teicoplanin MIC ≥4 mg/liter (n = 143) Dalbavancin 0.06 0.25 ≤0.03 to 0.5 95.1b 83.9 16.1 Daptomycin 0.5 1 0.12 to 4 95.8 95.8 4.2 Vancomycin 2 2 0.5 to 4 97.9 0.0 97.9 2.1 Teicoplanin 4 8 4 to 16 99.3 0.0 0.0 100.0 Linezolid 1 2 0.25 to 4 100.0 0.0 100.0 0.0 Oxacillin >2 >2 ≤0.25 to >2 26.6 73.4 26.6 73.4 Linezolid resistant (n = 25) Dalbavancin 0.06 0.06 ≤0.03 to 0.12 100.0b 100.0 0.0 Daptomycin 0.5 0.5 0.25 to 0.5 100.0 100.0 0.0 Vancomycin 1 2 0.5 to 2 100.0 0.0 100.0 0.0 Teicoplanin ≤2 ≤2 ≤2 to ≤2 100.0 0.0 100.0 0.0 Linezolid 8 >8 8 to >8 0.0 100.0 0.0 100.0 Oxacillin >2 >2 ≤0.25 to >2 4.0 96.0 4.0 96.0 - TABLE 2
Summary of dalbavancin activity tested against S. aureus isolates with decreased susceptibility to glycopeptides, daptomycin, and/or linezolid from U.S. medical centers
Resistance phenotype No. of isolates (cumulative %) inhibited at dalbavancin MIC (mg/liter) ofa: MIC50 (mg/liter) MIC90 (mg/liter) ≤0.03 0.06 0.12 0.25 0.5 Vancomycin MIC ≥2 mg/liter (n = 1,141) 117 (10.3) 697 (71.3) 276 (95.5) 43 (99.3) 8 (100.0) 0.06 0.12 Daptomycin nonsusceptible (n = 48) 3 (6.3) 25 (58.3) 16 (91.7) 2 (95.8) 2 (100.0) 0.06 0.12 Telavancin MIC ≥0.12 mg/liter (n = 52)b 4 (7.7) 24 (53.8) 16 (84.6) 3 (90.4) 5 (100.0) 0.0.6 0.25 Teicoplanin MIC ≥4 mg/liter (n = 143) 14 (9.8) 73 (60.8) 33 (83.9) 16 (95.1) 7 (100.0) 0.06 0.25 Linezolid resistant (n = 25) 5 (20.0) 18 (92.0) 2 (100.0) 0.06 0.06 All isolates (n = 59,903) 22,066 (36.8) 33,879 (93.4) 3,795 (99.7) 155 (>99.9) 8 (100.0) 0.06 0.06
